John Liu

Dr. John Jiangnan Liu, joined Johnson & Johnson in 2005, he is the founder of J&J Asia Pacific Emerging Markets Innovation Center. Dr. Liu has been actively driving smoking cessation in China. He participated in the development of first Smoking Cessation Guideline in China. He initiated China first smoking cessation program in hospitals to help Chinese doctors quit smoking. Dr. Liu has taken a very active role contributing to the advancement of Traditional Chinese Medicine. He collaborated with State Drug Administration of China to establish GAP (Good Agriculture Practice) regulation for Chinese medicine industry. He participated in Chinese medicine globalization strategic planning and proposed Chinese medicine globalization road map. Dr. Liu is regarded as an innovation champion in China. He has been invited to give speeches at numerous innovation conferences, and to give lecture in universities. He was also invited to give speeches at MNCs and Chinese local companies on innovation. Prior to Johnson & Johnson, Dr. Liu has been with GlaxoSmithKline for eight years, where he was Director for the New Products R&D Center in Tianjin, China. Prior to his China stint, he worked at GSK US as Associate Director of Smoking Control Open Innovation. Dr. Liu also spent two years at Warner‐Lambert (now Pfizer) and two years at Forest Lab on new drug development. Specialties: New Products Pipeline, New products development, Business Development, clinical trials, China SFDA, US FDA, TGA, India FDA, Philippine FDA etc. regulations, Corporate strategy